



European Monitoring Centre  
for Drugs and Drug Addiction



PROGRAMME

# Third international multidisciplinary forum on new drugs

27–28 June 2013

**Lisbon**

## **Organising committee**

### **EMCDDA**

Roumen Sedefov  
Andrew Cunningham  
Ana Gallegos  
Michael Evans-Brown  
Anabela Almeida  
Paulete Duque  
Kathy Robertson  
Paul Griffiths

### **Europol**

Klaidas Kuchalskis  
Daniel Dudek

### **Contacts**

Tel. (351) 211 21 02 00  
NewDrugForum@emcdda.europa.eu  
EWS@emcdda.europa.eu

### **Venue**

EMCDDA, Praça Europa, Cais do Sodré, Lisbon, Portugal

## | Third international multidisciplinary forum on new drugs

Only a few years ago, new psychoactive substances or ‘new drugs’ were generally regarded as being of limited significance to drug policy. The continued growth of the market, however — particularly the ‘legal highs’ phenomenon — has seen the issue develop into a complex policy challenge that is now of major international concern.

This market growth has been driven partly by entrepreneurs who have exploited gaps in drug regulation. It has also been fuelled by the increasingly globalised and interconnected world in which we live. The capacity to bulk synthesise new drugs in China and India, and then rapidly distribute and sell them on an open ‘legal highs’ market, is now beginning to impact on local, national, regional and international drug markets. The overall result of these developments has been the unprecedented rise in the number, type and availability of new drugs. Furthermore, there is a growing interplay between the new drugs and illicit drug markets. Not surprisingly, therefore, we are also seeing a greater role being played by criminal groups in this domain.

It was the early recognition of these developments that led to the *First international multidisciplinary forum on new drugs*, held in Lisbon in 2011. The event brought together stakeholders from across the globe to take stock of the new drugs phenomenon and identify common anchor points to inform future actions. Building on this event, the *Second interdisciplinary forum on new and emerging psychoactive substances* was held in Palm Springs in 2012, co-organised by the EMCDDA and the United States National Institute on Drug Abuse (NIDA). This focused on the growing global nature of the phenomenon and the importance of international cooperation in responding to the issue.

It is clear that a range of measures will be required to address the new drugs phenomenon. Moreover, a multidisciplinary approach will be crucial to understanding and responding to this problem in order to protect public health — which is at the very heart of the issue. It is with these key concepts in mind, and on this increasingly complex stage, that the EMCDDA, in cooperation with Europol, has organised this third forum.

Through thematic sessions, the forum will:

- review the state of play and provide a global overview of the new drugs phenomenon;
- identify key issues, commonalities and differences in the experience of, and response to, this phenomenon;
- explore the role that law enforcement can play;
- identify information gaps and research needs; and
- anticipate future developments and challenges.

The forum is organised in conjunction with the *13<sup>th</sup> Annual meeting of the Reitox early warning system (EWS) network* and the *Europol second law-enforcement meeting on new psychoactive substances*.

## Participants

The forum is an expert meeting, by invitation only, gathering over 100 invited participants. The event will bring together key European and international experts in the field of new drugs, creating a platform to discuss the latest developments in this area and to identify the challenges that need to be overcome.

Participants will include representatives of the Reitox national focal points from the 30 EMCDDA reporting countries — 27 EU Member States, Croatia, Turkey and Norway — as well as from the European Commission and the European Medicines Agency. Also invited are leading experts from Australia, Indonesia, Israel, Japan, New Zealand, Russia, Singapore, Switzerland, Ukraine and the United States. The participants have been selected for their technical expertise and research in the field of new drugs. Invited experts represent a wide range of disciplines, including: epidemiology, forensic science, healthcare, law enforcement, criminology and policy. Also participating are technical staff members from EU and international institutions.

## Themes

The third forum will be organised around the following thematic sessions:

- *New drugs: the big picture* — This session will set the scene of the forum. Keynote speeches will address distinct, yet connected, features of the new drugs phenomenon, including the: historical context, public health perspective, motivations of users, role of law enforcement and challenges for drug policy.
- *National, regional and global perspectives on new drugs* — Speakers from a range of countries and international organisations will present some of the significant developments and initiatives taking place around the globe.
- *Detecting, monitoring and understanding the emerging harms of new drugs* — This session will feature updates from forensic science, toxicology and healthcare, which together play a key role in understanding the emerging harms associated with new drugs.
- *The only constant is change: law enforcement and new drugs* — Although many new drugs are not controlled under international and national drug control legislation, it is recognised that there is a growing interplay between the new drug and the traditional illicit drug markets. Some of the law-enforcement initiatives in response to new drugs will be highlighted in this parallel session.
- *Reading the signals: keeping a finger on the pulse of new drugs* — Monitoring is one of the key elements to understanding the nature of the problem and the impact of responses. This session focuses on good practice, novel approaches and what we can learn from users of new drugs.
- *The response to new drugs: fit for purpose?* — Participants will hear about new drugs and related responses in New Zealand and will have the opportunity to discuss and debate key issues.

## Programme at a glance

<b>Thursday 27 June</b>	<b>13<sup>th</sup> Annual meeting of the Reitox early warning system network in conjunction with the Europol second law-enforcement meeting on new psychoactive substances</b>	
08.00–08.30	Registration	
08.30–10.30	Council Decision 2005/387/JHA on new psychoactive substances: implementation review 2012	
10.30–11.00	Break	
11.00–12.30	Nurturing the networks: Reitox and Europol	

<b>Thursday 27 June</b>	<b>Third international multidisciplinary forum on new drugs</b>	
12.30–13.45	Registration	
13.45–16.00	New drugs: the big picture	Session 1 Opening
16.00–16.30	Break	
16.30–18.30	National, regional and global perspectives on new drugs	Session 2
19.00	Reception	Poster session
<b>Friday 28 June</b>		
08.00–10.00	Detecting, monitoring and understanding the emerging harms of new drugs	Parallel session 3A
08.00–10.00	The only constant is change: law enforcement and new drugs	Parallel session 3B
10.00–10.30	Break	
10.30–12.30	Reading the signals: keeping a finger on the pulse of new drugs	Session 4
12.30–14.00	Lunch	
14.00–16.00	The response to new drugs: fit for purpose?	Session 5 Closing

## 13<sup>th</sup> Annual meeting of the Reitox early warning system network in conjunction with the Europol second law-enforcement meeting on new psychoactive substances

Thursday 27 June	
08.00–08.30	Registration
08.30–10.30	<p><b>Council Decision 2005/387/JHA on new psychoactive substances: implementation review 2012</b> Chairs — Roumen Sedefov and Ana Gallegos, EMCDDA</p> <p><b>Opening and introduction to the meeting</b> — Roumen Sedefov, EMCDDA</p> <p><b>Update on progress made in 2012</b></p> <ul style="list-style-type: none"> <li>• Implementation report on Council Decision — Andrew Cunningham, EMCDDA</li> <li>• Risk assessment of 4-methylamphetamine and 5-(2-aminopropyl)indole — Michael Evans-Brown, EMCDDA</li> <li>• Feedback from the trendspotter meeting on fentanyl — Jane Mounteney, EMCDDA</li> <li>• Feedback from Europol — Daniel Dudek, Europol</li> <li>• Update from the European Medicines Agency (EMA) — Jean-Marc Vidal, EMA</li> <li>• Update from the European Commission (EC) — Elsa Maia, EC</li> <li>• Feedback from the EWS correspondents</li> </ul> <p><b>Supporting the EWS network: high priorities</b> — Michael Evans-Brown, EMCDDA</p> <p><b>Discussion</b></p>
10.30–11.00	Break
11.00–12.30	<p><b>Nurturing the networks: Reitox and Europol</b> Chairs — Andrew Cunningham, EMCDDA and Klaidas Kuchalskis, Europol</p> <p><b>Introduction by Europol</b> — Daniel Dudek, Europol</p> <ul style="list-style-type: none"> <li>• Experience from the Italian national focal point — Claudia Rimondo, Italian national focal point</li> <li>• Experience from the Network for the Current Situation of Drugs in Nordic countries (NADIS) — Anders Persson and Sara Wall, Swedish national focal point</li> <li>• The Belgian experience — Benny van Camp, Belgian Federal Police and Peter Blanckaert, Belgian national focal point</li> </ul> <p><b>Discussion</b></p>

## Third international multidisciplinary forum on new drugs

Thursday 27 June		
12.30–13.45	Registration	
13.45–16.00	<b>Opening</b> — Wolfgang Götz, EMCDDA Director	
	<b>New drugs: the big picture</b> Chairs — Roumen Sedefov and Ana Gallegos, EMCDDA	Session 1 Opening
	<b>Introduction by the Chairs</b> <ul style="list-style-type: none"> <li>• Past, present and future of new drugs — Paul Griffiths, EMCDDA</li> <li>• Public health perspectives on new drugs: moving beyond neophobia — Harry Sumnall, Liverpool John Moores University, UK</li> <li>• Serving policy and practice: challenges to identifying new drugs — Barry Logan, NMS Labs, United States</li> <li>• How popular are new psychoactive substances (really)? Prevalence, patterns and preferences — Fiona Measham, Durham University, UK</li> <li>• The role of law enforcement: the DEA perspective — Terry Boos, Drug Enforcement Administration (DEA), United States</li> <li>• New drugs: the legal options — Angela Scrutton, Home Office, UK</li> </ul>	Forum keynotes
16.00–16.30	Break	
16.30–18.30	<b>National, regional and global perspectives on new drugs</b> Chairs — Paul Griffiths and Ana Gallegos, EMCDDA	Session 2
	<ul style="list-style-type: none"> <li>• The EU experience with new drugs: 15 years of regional monitoring — Andrew Cunningham, EMCDDA</li> <li>• New drugs in the US — Jane Maxwell, University of Texas at Austin, United States</li> <li>• Emerging psychoactive substances in Australia: the state of play — Lucy Burns, National Drug and Alcohol Research Centre, Australia</li> <li>• Update on the situation of new drugs in Japan — Ruri Kikura-Hanajiri, National Institute of Health Sciences, Japan</li> <li>• Asia, South America and Africa: emerging markets? — Beate Hammond, UNODC</li> <li>• New drugs: (what) can we learn from precursor control? — Barbara Remberg, INCB</li> <li>• Emergence of new psychoactive substances in Asia — Angeline Yap, the Asian Forensic Sciences Network, Singapore</li> <li>• Legal weapons against 'legal' drugs — Udi Wolf, Israel police</li> <li>• Spotlight on Russia — Ilya Shlykov, Federal Drug Control Service of the Russian Federation</li> <li>• Spotlight on Ukraine — Svetlana Sidiyak, Ukrainian Medical and Monitoring Centre on Alcohol and Drugs</li> </ul>	
19.00	Reception	Poster session

## Third international multidisciplinary forum on new drugs

Friday 28 June		
08.00–10.00	<p><b>Detecting, monitoring and understanding the emerging harms of new drugs</b> Chairs — Michael Evans-Brown, EMCDDA and Ruri Kikura-Hanajiri, National Institute of Health Sciences, Japan</p>	Parallel session 3A
	<p><b>New drugs: new harms? Experiences from clinical toxicology</b> Paul Dargan, Guy's and St Thomas' NHS Foundation Trust, UK</p>	Keynote
	<ul style="list-style-type: none"> <li>• Toxicovigilance and new drugs in Italy — Carlo Locatelli, Italian national focal point</li> <li>• Spice: monitoring new drugs in products and in forensic samples — Volker Auwärter, University Medical Centre Freiburg, Germany</li> <li>• The importance of monitoring patterns of use: injecting synthetic cathinones in Eastern Europe — Anna Péterfi, Hungarian national focal point</li> <li>• An introduction to -NBOMe chemistry — Simon Brandt, Liverpool John Moores University, UK</li> <li>• The clinical toxicology of 25I-NBOMe — Simon Hill, National Poisons Information Service, UK</li> </ul> <p><b>Discussion</b></p>	
08.00–10.00	<p><b>The only constant is change: law enforcement and new drugs</b> Chairs — Andrew Cunningham, EMCDDA and Klaidas Kuchalskis, Europol</p>	Parallel session 3B
	<p><b>Introduction by the Chairs</b></p> <ul style="list-style-type: none"> <li>• Diversification of the UK drugs market: law enforcement's response — Graeme Inglis, Serious Organised Crime Agency, UK</li> <li>• Investigating new drugs: what have we learned in Belgium? — Benny van Camp, Belgian Federal Police, Belgium</li> <li>• Joint analysis team: new psychoactive substances — Maria Instanes, Norwegian Customs and Excise, Norway</li> <li>• Current developments on new drugs in Germany: an operational case study — Anna Duffert, Federal Criminal Police Office, Germany</li> <li>• Case study: Operation Logjam — Terry Boos, DEA, United States</li> </ul> <p><b>Discussion</b></p>	
10.00–10.30	Break	



Friday 28 June		
10.30–12.30	<p><b>Reading the signals: keeping a finger on the pulse of new drugs</b> Chairs — Jane Mounteney, EMCDDA and Jane Maxwell, University of Texas at Austin, United States</p>	Session 4
	<b>Introduction by the Chairs</b>	
	<p><b>New synthetic drugs: a challenge for society</b> — Rainer Schmid, Medical University of Vienna, Austria</p>	Keynote
	<ul style="list-style-type: none"> <li>• Identifying new drugs in the UK: the Forensic Early Warning System — Sheila Hardwick, Home Office, UK</li> <li>• Monitoring drug markets in the Internet age — Lucy Burns, National Drug and Alcohol Research Centre, Australia</li> <li>• Legal or illegal, the substance effects are the key for users — Alexander Bücheli, City of Zurich, Social Welfare Department, Switzerland</li> <li>• Applications of sewage analysis in detection of new psychoactive substances — Juliet Kinyua, University of Antwerp, Belgium</li> <li>• Spicing things up: switching to synthetics to pass drug tests — Dina Perrone, California State University, United States</li> </ul> <p><b>Discussion</b></p>	
12.30–14.00	Lunch	
14.00–16.00	<p><b>The response to new drugs: fit for purpose?</b> Chairs — Roumen Sedefov and Jane Mounteney, EMCDDA</p>	Session 5 Closing
	<p><b>A critical assessment of the proposed regulated legal market for new psychoactive substances in New Zealand</b> — Chris Wilkins, Massey University, New Zealand</p>	Keynote
	<p><b>Perspectives</b></p> <ul style="list-style-type: none"> <li>• Identification — István Ujváry, iKem BT, Hungary</li> <li>• Law enforcement — Klaidas Kuchalskis, Europol</li> <li>• Care providers — Paul Dargan, Guy's and St Thomas' NHS Foundation Trust, UK</li> <li>• Users — Rainer Schmid, Medical University of Vienna, Austria</li> <li>• Public health, legislation and policy — Michael Evans-Brown, EMCDDA</li> </ul>	
	<p><b>Panel discussion and conclusions</b></p> <ul style="list-style-type: none"> <li>• Paul Griffiths, EMCDDA</li> <li>• Terry Boos, DEA, United States</li> <li>• Barry Logan, NMS Labs, United States</li> <li>• Angela Scrutton, Home Office, UK</li> <li>• Harry Sumnall, Liverpool John Moores University, UK</li> <li>• Chris Wilkins, Massey University, New Zealand</li> </ul>	
	<b>Closure</b>	

## | Selected publications in the area of new drugs

- *New drugs in Europe 2012. EMCDDA–Europol 2012 annual report on the implementation of Council Decision 2005/387/JHA.* EMCDDA, Lisbon, May 2013  
[www.emcdda.europa.eu/publications/implementation-reports/2012](http://www.emcdda.europa.eu/publications/implementation-reports/2012)
- *EMCDDA–Europol Joint report on a new psychoactive substance: 5-(2-aminopropyl) indole.* EMCDDA, Lisbon, February 2013  
[www.emcdda.europa.eu/publications/joint-reports/5-IT](http://www.emcdda.europa.eu/publications/joint-reports/5-IT)
- *EMCDDA–Europol Joint report on a new psychoactive substance: 4-methylamphetamine.* EMCDDA, Lisbon, November 2012  
[www.emcdda.europa.eu/publications/joint-reports/4-methylamphetamine](http://www.emcdda.europa.eu/publications/joint-reports/4-methylamphetamine)
- *EU drug markets report: a strategic analysis.* EMCDDA, Lisbon, January 2013  
[www.emcdda.europa.eu/publications/joint-publications/drug-markets](http://www.emcdda.europa.eu/publications/joint-publications/drug-markets)
- *Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances.* EMCDDA, Lisbon, May 2011  
[www.emcdda.europa.eu/html.cfm/index116639EN.html](http://www.emcdda.europa.eu/html.cfm/index116639EN.html)
- *Risk assessment of new psychoactive substances — operating guidelines.* EMCDDA, Lisbon, March 2010  
[www.emcdda.europa.eu/html.cfm/index100978EN.html](http://www.emcdda.europa.eu/html.cfm/index100978EN.html)
- *Early-warning system on new psychoactive substances — operating guidelines.* EMCDDA–Europol, Lisbon, October 2007  
[www.emcdda.europa.eu/html.cfm/index52448EN.html](http://www.emcdda.europa.eu/html.cfm/index52448EN.html)

## | Online resources

- Action on new drugs  
[www.emcdda.europa.eu/activities/action-on-new-drugs](http://www.emcdda.europa.eu/activities/action-on-new-drugs)
- Synthetic cannabinoids in Europe  
[www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids](http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids)
- Legal approaches to controlling new psychoactive substances  
[www.emcdda.europa.eu/topics/pods/controlling-new-psychoactive-substances](http://www.emcdda.europa.eu/topics/pods/controlling-new-psychoactive-substances)
- Drug profiles  
[www.emcdda.europa.eu/drug-profiles](http://www.emcdda.europa.eu/drug-profiles)

## **EMCDDA reporting countries**

27 EU Member States

Croatia

Turkey

Norway

## **Guest countries**

Australia

Indonesia

Israel

Japan

New Zealand

Russia

Singapore

Switzerland

Ukraine

United States

## **EU institutions**

European Commission

European Medicines Agency (EMA)

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

Europol

## **International**

United Nations Office on Drugs and Crime (UNODC)

International Narcotics Control Board (INCB)



emcdda

## **The EMCDDA and action on new drugs**

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union's decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe.

Since 1997, the EMCDDA has played a central role in the EU's response to new psychoactive substances ('new drugs'), which may pose health and social risks to our societies. Today, this activity is carried out under the terms of a legal instrument adopted by the Council of the European Union in 2005: the 'Council Decision on the information exchange, risk assessment and control of new psychoactive substances' (2005/387/JHA of 10 May 2005).

Within this legal framework, the EMCDDA and Europol operate the EU Early warning system on new psychoactive substances in conjunction with partners in the Member States, Croatia, Turkey and Norway, the European Medicines Agency and the European Commission.

This system ensures that partners have access to the most up-to-date information on new psychoactive substances, both from across Europe and beyond.

### **Action on new drugs**

[www.emcdda.europa.eu/activities/action-on-new-drugs](http://www.emcdda.europa.eu/activities/action-on-new-drugs)

### **Third international multidisciplinary forum on new drugs**

[www.emcdda.europa.eu/events/2013/new-drugs-forum](http://www.emcdda.europa.eu/events/2013/new-drugs-forum)